Biotechnology

Mustang Bio

Mustang Bio released FY2025 Q3 earnings on November 7, 2025 (EST) with actual revenue of USD 0 and EPS of USD -0.0749

Mustang Bio released FY2025 9 Months earnings on November 7, 2025 (EST), actual revenue USD 0, actual EPS USD -0.3179

Mustang Bio released FY2025 Q2 earnings on August 8 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.1894 (forecast USD --)

Mustang Bio released FY2025 Semi-Annual earnings on August 8 (EST), actual revenue USD 0, actual EPS USD -0.2656

Mustang Completes Non-Dilutive Private Placement to Strengthen Financial Position

Mustang Bio Receives FDA Orphan Drug Designation, MB-101 Phase 1 Trial Shows Positive Results

Mustang Bio released FY2025 Q1 earnings on May 14 EST, with actual revenue of USD 0 and EPS of USD -0.0534

Mustang Bio released FY2024 Q4 earnings on March 28 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -0.9411 USD (forecast -8 USD)

Mustang Bio released FY2024 annual earnings on March 28 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -25.8358 USD (forecast -30.5 USD)

Mustang Bio, Inc. Announces Public Offering of 2,657,807 Shares at $3.01 per Share, Aiming to Raise Approximately $8 Million

Mustang Bio released FY2024 Q3 earnings on November 8 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -1.9558 (forecast USD -6.5)

Mustang Bio released FY2024 9 Months Earnings on November 8 (EST), with actual revenue of USD 0 and EPS of USD -44.456

Mustang Bio released FY2024 Q2 earnings on August 13, 2024 (EST), with actual revenue of USD 0 (forecast USD 0) and actual EPS of USD -18.3592 (forecast USD -7)

Mustang Bio released FY2024 Semi-Annual Earnings on August 13 (EST), with actual revenue of 0 USD and EPS of -39.1733 USD

Mustang Bio, Inc. (MBIO) stock rises over 207%

Fortress Biotech Announces Positive Efficacy and Safety Data from Phase 1/2 Clinical Trial of MB-106 CD20-Targeted Autologous CAR-T Therapy

Mustang Bio released FY2024 Q1 earnings on May 15 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -24.8134 (forecast USD -11)

Marsden Bio Company Layoff Plan of 81%, Expected to Complete in Q2 2024

Mustang Bio released FY2023 Q4 earnings on March 11 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -43.0257 USD (forecast -66.5 USD)

Mustang Bio released FY2023 Annual Earnings on March 11, 2024 (EST): Actual Revenue 0 USD (Forecast 0 USD), Actual EPS -299.9575 USD (Forecast -333.75 USD)

Mega Fortune

Processa Pharmaceuticals

cbdMD

Agape ATP

VYNE Therapeutics

Andersen

Inspirato

Medline Inc.

Creative Global Tech

GCI LIBERTY INC COM USD0.01 SER C SUBS RTS 17/12/2025

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap